Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Acurx Pharmaceuticals, Inc. (ACXP : NSDQ)
 
 • Company Description   
Acurx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It focused on developing new antibiotics to treat infections. Acurx Pharmaceuticals Inc. is based in STATEN ISLAND, N.Y.

Number of Employees: 3

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.70 Daily Weekly Monthly
20 Day Moving Average: 15,861 shares
Shares Outstanding: 10.26 (millions)
Market Capitalization: $27.71 (millions)
Beta:
52 Week High: $8.74
52 Week Low: $2.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -28.76% -21.94%
12 Week -34.15% -28.55%
Year To Date -37.52% -25.70%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
259 LIBERTY AVENUE
-
STATEN ISLAND,NY 10305
USA
ph: 917-533-1469
fax: -
davidluci@acurxpharma.com http://www.acurxpharma.com
 
 • General Corporate Information   
Officers
David P. Luci - Chief Executive Officer and President
Robert J. DeLuccia - Executive Chairman
Robert G. Shawah - Chief Financial Officer
Carl V. Sailer - Director
Joseph C. Scodari - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00510M104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 10.26
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $27.71 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.59
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -13.04%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -105.43
12/31/21 - -114.12
09/30/21 - -128.25
ROA
03/31/22 - -97.83
12/31/21 - -104.77
09/30/21 - -116.09
Current Ratio
03/31/22 - 17.89
12/31/21 - 15.70
09/30/21 - 21.05
Quick Ratio
03/31/22 - 17.89
12/31/21 - 15.70
09/30/21 - 21.05
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.04
12/31/21 - 1.23
09/30/21 - 1.41
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©